Stacey E. P. Joosten

Stacey E. P. Joosten

Auto-generated profile, based on publicly available information

Stacey E. P. Joosten

Division of Oncogenomics, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications: Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.

3 July 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJeroen van Den Berg
Jeroen van Den Berg
SJStacey E.P. Joosten
Stacey E.P. Joosten
YKYongSoo Kim
YongSoo Kim
AMAnna G. Manjón
Anna G. Manjón
LKLenno Krenning
Lenno Krenning
RMRené H. Medema
René H. Medema
Of all damage occurring to DNA, the double strand break (DSB) is the most toxic lesion. Luckily, cells have developed multiple repair pathways to cope with these lesions. These different pathways compete for the same break, and the location of the break can influence this competition. However, the exact contribution of break location in repair pathway preference is not fully understood. We observe that most breaks prefer classical non-homologous end-joining, whereas some depend on DNA end-resection for their repair. Surprisingly, we find that for a subset of these sites, the activation of resection-dependent repair induces a detrimental DNA damage response. These sites exhibit extensive DNA end-resection due to improper recruitment of 53BP1 and the Shieldin complex due to low levels of H4K20me2. Most of these sites reside in close proximity to DNAseI hypersensitive sites. Compacting or removing these regions reduces extensive DNA end-resection and restores normal repair. Taken together, we found that DSB in open chromatin is highly toxic, due to the improper activity of 53BP1 and Shieldin, resulting in extensive DNA end-resection.

6 May 2024 in Genome Research
Verified
Journal Article
Open access
PDF file
SJStacey E.P. Joosten
Stacey E.P. Joosten
SGSebastian Gregoricchio
Sebastian Gregoricchio
SSSuzan Stelloo
Suzan Stelloo
EYElif Yapıcı
Elif Yapıcı
CHChia-Chi Flora Huang
Chia-Chi Flora Huang
WZWilbert Zwart
Wilbert Zwart
Estrogen Receptor 1 (ESR1; also known as ERα, encoded byESR1gene) is the main driver and prime drug target in luminal breast cancer. ESR1 chromatin binding is extensively studied in cell lines and a limited number of human tumors, using consensi of peaks shared among samples. However, little is known about inter-tumor heterogeneity of ESR1 chromatin action, along with its biological implications. Here, we use a large set of ESR1 ChIP-seq data from 70 ESR1+breast cancers to explore inter-patient heterogeneity in ESR1 DNA binding to reveal a striking inter-tumor heterogeneity of ESR1 action. Of note, commonly shared ESR1 sites show the highest estrogen-driven enhancer activity and are most engaged in long-range chromatin interactions. In addition, the most commonly shared ESR1-occupied enhancers are enriched for breast cancer risk SNP loci. We experimentally confirm SNVs to impact chromatin binding potential for ESR1 and its pioneer factor FOXA1. Finally, in the TCGA breast cancer cohort, we can confirm these variations to associate with differences in expression for the target gene. Cumulatively, we reveal a natural hierarchy of ESR1–chromatin interactions in breast cancers within a highly heterogeneous inter-tumor ESR1 landscape, with the most common shared regions being most active and affected by germline functional risk SNPs for breast cancer development.

3 April 2023
Verified
Other
Open access
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
Supplemental Figure 1. Tamoxifen treatment induces expression of NFκBB-related genes. Supplementary Figure 2. Immune cell composition and numbers in the tumor microenvironment do not significantly change upon tamoxifen treatment. Supplementary Figure 3. NFκB pathway and EMT/stemness factors in tamoxifen-tolerant persisters in T47D cells. Supplementary Figure 4. Expression of p65 and p50 proteins in MCF-7 CRISPR/Cas9 knock out clones. Supplementary Figure 5. NFκB pathway is not directly activated by tamoxifen. Supplementary Figure 6. Sorted NFκB+ vs NFκBâ^' or unsorted tamoxifen-tolerant cells based on GFP expression were reseeded for another round of clonogenic assay and the %GFP+ population was quantified in the second round.

3 April 2023
Verified
Other
Open access
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
Supplemental Table 3. GSEA enrichment plots

3 April 2023
Verified
Other
Open access
IKIrida Kastrati
Irida Kastrati
SJStacey E. P. Joosten
Stacey E. P. Joosten
SSSvetlana E. Semina
Svetlana E. Semina
LALuis H. Alejo
Luis H. Alejo
SBSvitlana D. Brovkovych
Svitlana D. Brovkovych
JFJonna Frasor
Jonna Frasor
Supplemental Table 1. Patient characteristics.